このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cassava Sciences, Inc. 競合他社
価格と性能
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.88 |
| 52 Week High | US$32.10 |
| 52 Week Low | US$12.32 |
| Beta | -0.49 |
| 1 Month Change | -14.01% |
| 3 Month Change | -9.60% |
| 1 Year Change | -19.19% |
| 3 Year Change | -77.84% |
| 5 Year Change | 1,383.58% |
| Change since IPO | -87.02% |
最新ニュース
Recent updates
Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Oct 17
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Jul 04We're Not Very Worried About Cassava Sciences' (NASDAQ:SAVA) Cash Burn Rate
Mar 05Cassava Sciences (NASDAQ:SAVA) Is In A Good Position To Deliver On Growth Plans
Nov 19Cassava Sciences begins extension study of Alzheimer's drug simufilam
Oct 13Cassava Sciences Stock: Huge Returns Or Catastrophic Losses
Sep 29Cassava Sciences: Trying To Manage Expectations
Sep 21Cassava Sciences reaches over five-month high on rising volumes
Sep 09Cassava Sciences Looks As Good Of A Purchase As Ever
Sep 03Cassava Sciences stock jumps 10% after director buys $860K shares
Aug 26Cassava Sciences rally continues as stock up 39%
Aug 17Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results
Aug 11Cassava Sciences GAAP EPS of -$0.48 misses by $0.06
Aug 03We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely
Aug 03Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug
Jul 27Cassava Sciences And Alzheimer's Disease: A Precipitious Path
Jun 10Cassava Sciences: 3 Upcoming Catalysts That Could Decide Bull / Bear Debate
May 31Cassava Sciences (NASDAQ:SAVA) has More Than Enough Funding to Function Until the Approval Process is Finished, but Investors may Need to be Ready for a Long Wait
Apr 193 Key Points To Remember About Cassava Sciences
Apr 07Retractions Of A Key Collaborator's Papers Set Up A Big April For Cassava Sciences
Mar 31Cassava Sciences: Why The Stock Is Rangebound
Feb 28The FDA Deals Another Blow To Cassava Sciences' Bears
Feb 11Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity
Feb 02INmune Bio, The Biotech In My Stable For After Cassava Sciences
Jan 17Cassava Sciences, Inc. - The Short Squeeze Has Started
Jan 06Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam
Dec 30Companies Like Cassava Sciences (NASDAQ:SAVA) Are In A Position To Invest In Growth
Dec 28Cassava Sciences Stock: Here We Go Again
Dec 21Cassava Sciences Teaches Us 4 Lessons To Find The Next Big Thing
Dec 02Cassava Sciences Gets Underway Putting Simufilam To The Test
Nov 24Cassava Sciences: Data Rules!
Nov 17Cassava Sciences' Hypothesis Raises Doubts
Nov 08Cassava Sciences Stock: Massive Potential Marred By Controversy
Nov 01Cassava Sciences: Welcome To The Casino
Oct 25Has Cassava Sciences Put Out The Fire For Now?
Sep 28Cassava Sciences: Medical History In The Making
Sep 21Cassava Sciences: One Doubtful Drug For One Doubtful Indication
Sep 15We Think Cassava Sciences (NASDAQ:SAVA) Can Afford To Drive Business Growth
Sep 14More On Cassava Sciences' Controversy
Sep 04Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
Aug 26株主還元
| SAVA | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 3.9% | -0.5% | 1.6% |
| 1Y | -19.2% | 16.6% | 21.5% |
業界別リターン: SAVA過去 1 年間で17 % の収益を上げたUS Pharmaceuticals業界を下回りました。
リターン対市場: SAVAは、過去 1 年間で20.8 % のリターンを上げたUS市場を下回りました。
価格変動
| SAVA volatility | |
|---|---|
| SAVA Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: SAVAの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: SAVAの weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1998 | 29 | Remi Barbier | www.cassavasciences.com |
キャッサバ・サイエンス社は臨床段階のバイオテクノロジー企業で、神経変性疾患の治療薬を開発している。同社の主要治療薬候補は、第2相臨床試験を完了した低分子薬simufilamであり、治験診断薬候補は、アルツハイマー病を検出する血液ベースのバイオマーカー/診断薬SavaDxである。同社は以前はPain Therapeutics, Inc.として知られていたが、2019年3月にCassava Sciences, Inc.に社名を変更した。カッサバ・サイエンシズ・インクは1998年に法人化され、テキサス州オースティンを拠点としている。
Cassava Sciences, Inc. 基礎のまとめ
| SAVA 基礎統計学 | |
|---|---|
| 時価総額 | US$946.09m |
| 収益（TTM） | -US$47.90m |
| 売上高(TTM) | n/a |
0.0x
P/Sレシオ-19.9x
PER（株価収益率SAVA は割高か？
公正価値と評価分析を参照収益と収入
| SAVA 損益計算書（TTM） | |
|---|---|
| 収益 | US$0 |
| 売上原価 | US$83.54m |
| 売上総利益 | -US$83.54m |
| その他の費用 | -US$35.63m |
| 収益 | -US$47.90m |
直近の収益報告
Mar 31, 2024
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.00 |
| グロス・マージン | 0.00% |
| 純利益率 | 0.00% |
| 有利子負債／自己資本比率 | 0% |
SAVA の長期的なパフォーマンスは？
過去の実績と比較を見る